1

Overview

Sources in this part

  1. 1Gindri et al., 2024

NADH is the reduced form of the coenzyme NAD, and the app lists it as an oral supplement in the coenzyme subcategory. A 2024 systematic review describes nicotinamide adenine dinucleotide as "an essential pyridine nucleotide cofactor that is present in cells".1 The app's notes separate NADH from the NAD+ precursors NMN and NR, which the body must convert, and describe NADH as the finished reduced coenzyme. The same notes call oral bioavailability of NADH an open question and say that sublingual and enteric forms aim to address it.

Gindri and colleagues, in the American Journal of Physiology-Endocrinology and Metabolism in 2024, set out "to examine whether the coenzyme formulae NAD+ and NADH are safe and effective when acting as a supplement to humans".1 The review "includes 10 studies, with a total of 489 participants", covering chronic fatigue syndrome, older adults, Parkinson's disease, overweight, postmenopausal prediabetes and Alzheimer's disease.1 Its trials covered NADH and also NAD precursors, so its pooled statements are not statements about NADH alone.1 The authors conclude that "NADH supplementation is safe and has a low incidence of side effects" and that "Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered".1 Two of the seven authors list bio meds Pharma, Florianópolis, Brazil as their affiliation, and the record names a grant from Brazil's CNPq; it carries no conflict-of-interest statement.1

The app grades the evidence for NADH as emerging.

Swerdlow, in a 1998 review in Drugs & Aging, describes a proposed mechanism in Parkinson's disease: NADH "indirectly supplies reducing equivalents to the rate-limiting, tyrosine hydroxylase-catalysed step of dopamine synthesis".2 The same review lists "claims that NADH stimulates tyrosine hydroxylase and dopamine biosynthesis in tissue culture and humans" as support for the idea.2 It also lists arguments against: "underlying NADH disposal impairment in PD and failure of a placebo-controlled trial to show any clear benefit".2 Forsyth and colleagues (Georgetown University School of Medicine, Annals of Allergy, Asthma & Immunology, 1999) write that nicotinamide adenine dinucleotide "is known to trigger energy production through ATP generation which may form the basis of its potential effects".3 Castro-Marrero and colleagues (Antioxidants & Redox Signaling, 2015) describe NADH as "a coenzyme that can stimulate energy production by replenishing depleted cellular stores of ATP".4 These are the authors' proposals; the records listed in two PubMed queries include no study of the mechanism of oral NADH in people.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
30%
Typical dose
5–20 mg/day
Route
Oral
Time to peak
~1 h

The app lists a half-life of 1 hour, oral bioavailability of 30% and a time to peak of 1 hour, in a one-compartment model. No human pharmacokinetic study of oral NADH was identified in PubMed, so the sources give no figure to set beside the app's half-life, bioavailability or time to peak.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~1 hNo human figure identified in PubMed
Bioavailability30%No figure identified; the app's notes call it an open question
Time to peak~1 hNo figure identified in PubMed

Forsyth and colleagues tested "ENADA the stabilized oral absorbable form" of NADH.3 Birkmayer and colleagues (Wiener Medizinische Wochenschrift, 2002) tested "a stabilized, sublingual form of reduced nicotinamide adenine dinucleotide".5 Castro-Marrero and colleagues (Nutrients, 2021) used "four enteric-coated tablets daily consisting of active ingredients (50 mg of CoQ10 and 5 mg of NADH)".6

4

Human studies

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Forsyth and colleagues, Annals of Allergy, Asthma & Immunology, 19993Randomised, double-blind, placebo-controlled crossover; NADH alone326 patients meeting CDC criteria for chronic fatigue syndrome who completed the study310 mg NADH or placebo for 4 weeks, 4-week washout, then the other arm for 4 weeks38 of 26 (31%) responded favourably to NADH against 2 of 26 (8%) to placebo; no severe adverse effects related to the study drug3
Alegre and colleagues, Revista Clinica Espanola, 20107Double-blind, placebo-controlled, 3-month trial; NADH alone786 patients with chronic fatigue syndrome enrolled, 77 completed (mean age 47 years, 72 women)720 mg oral NADH or placebo during the first two months7No significant differences in most variables; anxiety 1.0 point lower with NADH (p below 0.05) against 0.2 lower with placebo (not significant); maximum heart rate after the stress test fell by a mean of 8.1 per minute with NADH (p below 0.05) and rose by 1.7 per minute with placebo (p = 0.73); no difference in perceived efficacy7
Castro-Marrero and colleagues, Antioxidants & Redox Signaling, 20154Randomised, double-blind, placebo-controlled, 8 weeks; NADH plus coenzyme Q10473 women with chronic fatigue syndrome (39 active, 34 placebo)420 mg/day NADH plus 200 mg/day coenzyme Q10, 8 weeks4Fatigue Impact Scale total score lower than placebo (p below 0.05); no adverse effects seen or reported4
Castro-Marrero and colleagues, Clinical Nutrition, 20168Proof-of-concept, randomised, double-blind, placebo-controlled, 8 weeks; NADH plus coenzyme Q10880 patients with chronic fatigue syndrome8CoQ10 plus NADH or matching placebo twice daily, 8 weeks8Maximum heart rate on a cycle ergometer test lower at week 8 than at baseline (P = 0.022); fatigue lower than placebo (P = 0.03); pain and sleep did not improve8
Castro-Marrero and colleagues, Nutrients, 20216Randomised, double-blind, placebo-controlled, 12 weeks (8 weeks of supplement, 4 weeks after); NADH plus coenzyme Q106207 women with ME/CFS randomised, 144 completed (72 per group)620 mg NADH plus 200 mg coenzyme Q10 daily in four tablets, 8 weeks6Improvements within the active group over time; "no differences were found in the intergroup analysis"; 19 dropouts for adverse effects (8 active, 11 placebo)6
Birkmayer W and colleagues, Journal of Neural Transmission, 19899Open-label; the record describes no comparator; intravenous NADH934 patients with Parkinson's disease9Intravenous; dose and length not given in the record9All 34 improved: 21 (61.7%) by more than 30% and 13 (38.3%) by up to 30% on a disability measure; urine homovanillic acid rose9
Birkmayer JG and colleagues, Acta Neurologica Scandinavica Supplementum, 199310Open-label; the record describes no comparator; intravenous or oral NADH10885 patients with Parkinson's disease10About half intravenous infusion, the rest oral capsules; dose and length not given in the record10Beneficial clinical effect in about 80%: 19.3% very good (30-50%) and 58.8% moderate (10-30%) improvement; 21.8% did not respond10
Birkmayer GD and colleagues, Wiener Medizinische Wochenschrift, 20025Randomised, double-blind, placebo-controlled; sublingual NADH535 healthy employed adults after an overnight flight with a 3-hour time difference520 mg sublingual NADH (n = 18) or placebo (n = 17) given on arrival; number of doses not given in the record5NADH group performed significantly better on 4 cognitive test measures and reported less sleepiness; no adverse effects observed5

Deeper analysis: NADH plus coenzyme Q10 in ME/CFS (Castro-Marrero, 2021)

Castro-Marrero and colleagues (Vall d'Hebron Hospital Research Institute, Barcelona, with Vitae Health Innovation) reported a single-centre trial in Nutrients in 2021 that tested NADH only in combination with coenzyme Q10.6 Eligible participants were women aged 18 or older with a confirmed ME/CFS diagnosis by the 1994 CDC/Fukuda definition, and 35 of 242 screened were excluded.6 The active tablets held 5 mg NADH and 50 mg coenzyme Q10, with 20 mg phosphatidylserine and 40 mg vitamin C as excipients, and the placebo tablets "only excipients".6 The primary measure was the change in the Fatigue Impact Scale (FIS-40) from baseline to the final visit; the study "was powered to detect a 3-point difference between active treatment group and placebo".6 The sample-size calculation called for "a total of 121 subjects in each group", and 72 per group completed.6 Within the active group, cognitive fatigue improved at 4 and 8 weeks (p = 0.005 and p = 0.010), and the total FIS-40 score fell at 4 weeks (p = 0.022) but not at 8 weeks or 4 weeks after treatment (p = 0.089 and p = 0.071).6 The authors write that the improvements were seen "in the intragroup analysis, although no differences were found in the intergroup analysis".6 The Results text reports a sleep-duration difference at 4 weeks (p = 0.018) as a between-group comparison, while the paper's summary describes the same p value as a change from baseline within the experimental group and its table shows the groups already differed at baseline (p = 0.017); six SF-36 domains "did not show any differences in the between-group comparison analysis".6 The paper's summary gives a different p value for cognitive fatigue from its Results text, which gives p = 0.005 and p = 0.010 at weeks 4 and 8.6 On safety, "19 subjects dropped out due to adverse effects": eight on active (five epigastralgias, three dizziness) and eleven on placebo (four epigastralgias, five dizziness, one diarrhea, one muscle spasm).6 A further 24 were lost to follow-up (13 active, 11 placebo), and the authors report that "No serious adverse events or suspected adverse reactions" occurred.6 Four more discontinued because of a concurrent process (one case of anemia in the active group) and 16 withdrew at their own request (nine active, seven placebo).6 The authors name four limitations: the primary endpoint "is a subjective parameter"; all patients were "Caucasian ME/CFS women" from one tertiary centre; the lack of between-group differences "may have been due to the placebo effect (phosphatidylserine and vitamin C as excipients)"; and doses and follow-up timing "were pre-established".6 Funding: "Vitae Health Innovation Co. supplied both treatments", one author "received financial support and honoraria" from the company, and another is a company employee; the paper adds that "the funders declare that they had no role in the design, execution, analysis and interpretation, and presentation of data".6 The paper also records partial support from the Vall d’Hebron Hospital Research Institute.6 The registry entry (NCT03186027) lists the Vall d'Hebron Research Institute as lead sponsor with Vitae Health Innovation, class industry, as collaborator, gives an actual enrollment of 282 where the paper reports 242 screened and 207 randomised, and describes the daily amount as "divided into 2 daily dose" where the paper's summary says "once daily".11,6 The study cannot separate the effect of NADH from that of coenzyme Q10; the authors chose the pair "in light of reports that they may have synergistic antioxidant effects".6

Deeper analysis: NADH plus coenzyme Q10 in CFS (Castro-Marrero, 2015 and 2016)

Castro-Marrero and colleagues reported biochemical and fatigue results in Antioxidants & Redox Signaling in 2015 and the registered primary outcome, maximum heart rate, in Clinical Nutrition in 2016; the registry lists both as derived from NCT02063126.4,8,12 The 2015 paper enrolled 73 women, the 2016 paper 80 patients, and the registry gives an actual enrollment of 80.4,8,12 In the 2015 paper the Fatigue Impact Scale total score was reported lower than placebo after 8 weeks, with a p value below 0.05.4 In the paper's table only the total score is marked as significantly different from placebo at 8 weeks; the physical, cognitive and psychosocial subscale rows carry no such mark.4 The paper also measured blood mononuclear cell values: NAD+ was lower in the treated group (86.9±1.4 against 189.4±8.9 pmol/106 cells), NADH higher (247.3±5.1 against 98.2±4.6) and the NAD+/NADH ratio lower (0.36±0.009 against 1.92±0.038).4 The summary of the same paper lists NAD+/NADH among the parameters that were "significantly higher" in the treated group, which differs from the lower ratio in its Results text.4 CoQ10, ATP and citrate synthase were reported higher and lipoperoxides lower in the treated group, all with p below 0.05.4 The authors state that whether altered NAD+/NADH levels in CFS are "actively and directly associated with the pathogenesis of illness or represents an epiphenomenon" remains unclear.4 The record of the 2016 paper reports the maximum heart rate result against baseline within the active group (P = 0.022) and the fatigue result against placebo (P = 0.03); it states that "pain and sleep did not improve in the active group" and that the combination "was generally safe and well tolerated".8 The 2016 authors conclude that "Further additional larger controlled trials are needed to confirm these findings".8 Funding and ties: the acknowledgements of the 2015 paper state that "This work has been supported by VITAE NATURAL NUTRITION, S.L.", the registry lists that company as a collaborator, and one author of the 2015 paper and one of the 2016 paper list Vitae Natural Nutrition as their affiliation; the 2015 full text holds no conflict-of-interest or limitations statement.4,12,8

Deeper analysis: NADH alone in chronic fatigue syndrome (Forsyth, 1999; Alegre, 2010)

Forsyth and colleagues called their study a pilot; the crossover design gave each of 26 completers both NADH and placebo, and the record reports 8 responders on NADH and 2 on placebo without stating how a favourable response was defined.3 The authors write that "Based upon these encouraging results we have decided to conduct an open-label study in a larger cohort of patients".3 The record lists G.D. Birkmayer among the authors and names the ENADA product; it labels the work "Research Support, Non-U.S. Gov't" and does not name a funder or state limitations.3 Alegre and colleagues (Hospital Vall d'Hebron, Barcelona) report that "No significant differences were found in most of the variable studied at the end of the study".7 Two differences were reported: anxiety fell by 1.0 point with NADH (p below 0.05) and 0.2 points with placebo (not significant), and maximum heart rate after the stress test fell by a mean of 8.1 per minute with NADH (p below 0.05) and rose by 1.7 per minute with placebo (p = 0.73).7 The conclusion states that "this treatment did not modify other clinical variables and the global functional performance".7 The record gives no discontinuation reasons, funder or limitations; it labels the work "Research Support, Non-U.S. Gov't".7

Deeper analysis: Parkinson's disease reports (Birkmayer, 1989 and 1993)

Both reports come from the Birkmayer-Institut für Parkinsontherapie in Vienna and both describe an open-label trial; neither record describes a comparator.9,10 In the 1989 report all 34 patients had a beneficial effect, and the daily "on phases" were reported to increase "from 2 up to 9 hours in the individual patients".9 In the 1993 report of 885 patients, about half received NADH intravenously and the rest orally, and "The orally applied form of NADH yielded an overall improvement in the disability which was comparable to that of the parenterally applied form".10 Improvement was weakly related to age, disease duration and baseline disability: "younger patients and patients with a shorter duration of disease have a better chance to gain a marked improvement than older patients and patients with longer duration of the disease".10 Swerdlow's 1998 review describes the support as "case series" and states that "recommendations for its use in PD are premature".2 The two Birkmayer records give no funder, limitations or dose, and the placebo-controlled trial Swerdlow mentions is not among the sources read.2

Deeper analysis: jet lag trial (Birkmayer, 2002)

Birkmayer, Kay and Vurre (Labor Birkmayer & MEDINFO GmbH, Vienna) tested a sublingual product named "ENADAlert, Menuco Corp." in 35 people who flew overnight across a 3-hour time difference.5 Jet lag "resulted in increased sleepiness for over half the participants and deterioration of cognitive functioning for approximately one third", and NADH was reported to give better results on 4 cognitive measures (P of .05 or below) and less sleepiness.5 The record states that "No adverse effects were observed with NADH treatment" and does not report limitations or a funder.5

5

Doses reported in studies and on labels

The app lists a typical dose of 5 to 20 mg/day. No single-ingredient NADH label was identified: a DailyMed search for "NADH" returned 11 labels, each a multi-ingredient product.

Table 5.1Doses reported in studies and on labels7 rows
Study and yearDose and routeComparatorLengthn
Forsyth, 1999310 mg NADH, oralPlacebo, crossover4 weeks per arm, 4-week washout26 completers
Alegre, 2010720 mg NADH, oralPlaceboFirst two months of a 3-month trial86 enrolled, 77 completed
Castro-Marrero, 2015420 mg/day NADH plus 200 mg/day coenzyme Q10, oral, two daily dosesMatching placebo8 weeks73
Castro-Marrero, 20168CoQ10 plus NADH, oral, twice daily; NADH amount not given in the recordMatching placebo8 weeks80
Castro-Marrero, 2021620 mg NADH plus 200 mg coenzyme Q10, oral, four tablets daily (5 mg and 50 mg each)Matching placebo8 weeks of supplement, 4 weeks after207 randomised, 144 completed
Birkmayer GD, 2002520 mg NADH, sublingualPlacebo tabletsGiven on arrival; number of doses not given in the record35 (18 NADH, 17 placebo)
Birkmayer JG, 199310NADH by intravenous infusion or oral capsules; dose not given in the recordNone (open label)Not given in the record885

Forsyth and colleagues reported "No severe adverse effects" related to the study drug, the jet lag trial reported that "No adverse effects were observed", and the 2015 trial reported that "No adverse effects were seen or reported by patients".3,5,4 In the largest randomised trial (207 randomised), 19 participants dropped out for adverse effects (epigastralgias, dizziness, diarrhea, muscle spasm), 8 on the NADH plus coenzyme Q10 product and 11 on placebo.6 The Gindri review states that "All studies showed some side effects" and lists "muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches" as the most common with NAD products; it adds that the events "did not present a serious risk to the health of the participants".1 The two animal reports read both come from one laboratory, Birkmayer Laboratories in Vienna.13,14 In a 26-week study of 80 rats (40 males and 40 females) divided into two groups, one group received one 5 mg ENADA/NADH tablet daily and the other placebo tablets; "There were no deaths associated with the study drug and no treatment-releated clinical signs", although in weeks 13 to 26 females treated with NADH "gained significantly" more body weight than the controls.13 From about week 15, the treated females consumed up to 10% more food than the controls.13 In beagle dogs given oral doses of 20, 100 and 150 mg/kg for 14 days, the authors report "no signs of a toxicological effect" and "A transitory change in stool formation" with the intermediate and high dose in males.14 The same record reports "apparent increases in adrenal, heart, kidney, liver, brain, and thyroid weights, particularly in males", which the authors did not consider toxicologically significant.14 With intravenous dosing in dogs, "food consumption and body weight were reduced" at 500 mg/kg/day and above, and the maximum tolerated intravenous dose was taken as 500 mg/kg/day.14 At intravenous doses between 100 and 1000 mg/kg/day the authors also report effects on the cardiovascular system and some evidence of an effect on the central nervous system and on the adrenals.14

7

Bloodwork and markers

The app lists no health markers to monitor for NADH. The trials above measured symptom scales, maximum heart rate on exercise tests, urine homovanillic acid (the Parkinson's reports) and, in one trial, blood mononuclear cell levels of NAD+, NADH, coenzyme Q10, ATP, citrate synthase and lipoperoxides.4,9

8

Regulatory and anti-doping status

The word NADH did not appear in the text of the WADA 2026 Prohibited List that was retrieved, and the list's monitoring-program note names nicotine, not NADH.15 Whether the retrieved text is the complete list was not verified.15 The registry entry for NCT03186027 records "Is Fda Regulated Drug: false" for the NADH plus coenzyme Q10 supplement.11 The DailyMed search for "NADH" returned no single-ingredient NADH label; no other regulatory source was searched.

No human pharmacokinetic study of oral NADH was identified in PubMed, so the half-life, bioavailability and time to peak the app lists have no published figure beside them in the sources read. No pharmacokinetic study in the sources read tested whether orally taken NADH reaches the blood or tissues as NADH; one trial measured NADH in blood mononuclear cells after oral NADH plus coenzyme Q10 and reported higher levels than placebo, and the app's notes call oral bioavailability an open question.4 Three of the five chronic fatigue syndrome reports tested NADH together with coenzyme Q10, so no result there can be assigned to NADH alone.6 The two NADH-alone chronic fatigue trials had 26 completers (Forsyth, called a pilot study by its authors) and 86 enrolled (Alegre), and reported mixed results: 8 of 26 responders on NADH against 2 on placebo in the first, and no significant differences in most variables in the second.3,7 The Parkinson's reports of NADH in the sources are open-label, and Swerdlow's review lists the failure of a placebo-controlled trial to show any clear benefit among the arguments against NADH.2 Most trials read came from authors linked to one of two groups, the Birkmayer group in Vienna or the Vall d'Hebron group in Barcelona with Vitae, and no NADH trial from a group unconnected to either was among the records listed for the two PubMed queries run. Of the first 20 records listed for "NADH cognitive function Alzheimer's", none was a trial of NADH in people with cognitive impairment.

What is the half-life of NADH?

The app lists a half-life of about 1 hour for NADH. No human half-life figure was identified in the sources searched.

What is the bioavailability of oral NADH?

The app lists oral bioavailability of 30%. The app's notes call oral bioavailability an open question, and none of the trials or reviews read gives a figure.

How long does NADH take to reach its peak level?

The app lists a time to peak of about 1 hour. No time-to-peak figure was identified in the sources searched.

Is NADH the same as NAD+?

NADH is the reduced form of the coenzyme NAD. The app's notes distinguish NADH from the NAD+ precursors NMN and NR, which the body must convert.

Is NADH banned by WADA?

The word NADH did not appear in the WADA 2026 Prohibited List text that was retrieved.15 The completeness of that retrieved text was not verified.15

Has NADH been tested in chronic fatigue syndrome?

Randomised, placebo-controlled trials in chronic fatigue syndrome are reported for NADH alone in 26 completers (Forsyth, 1999) and 86 enrolled patients (Alegre, 2010).3,7 Alegre and colleagues reported "No significant differences" in most variables.7 Forsyth and colleagues reported that 8 of 26 (31%) responded favourably to NADH against 2 of 26 (8%) to placebo.3 Trials of NADH combined with coenzyme Q10 also exist, from the Vall d'Hebron group in Barcelona.6,4 In the largest of these (Castro-Marrero, 2021) the authors report improvement within the active group "although no differences were found in the intergroup analysis".6

What did the Parkinson's disease studies of NADH show?

Two open-label reports, with no comparator described in the records, described improvement in disability: all 34 patients given intravenous NADH in 1989, and about 80% of 885 patients (about half intravenous, the rest oral capsules) in 1993.9,10 Swerdlow's 1998 review said that "recommendations for its use in PD are premature".2

What side effects were reported with NADH in trials?

Forsyth and colleagues reported no severe adverse effects related to the study drug, the jet lag trial and the 2015 trial reported no adverse effects, and the 2021 trial reported 19 dropouts for adverse effects across both arms (8 on NADH plus coenzyme Q10, 11 on placebo) and no serious adverse events.3,5,4,6

Is NADH an approved drug?

No single-ingredient NADH medicine label was identified in a DailyMed search, which returned 11 multi-ingredient labels.

12

References

  1. Gindri IM, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab 2024. PMID 37971292
  2. Swerdlow RH. Is NADH effective in the treatment of Parkinson's disease? Drugs Aging 1998. PMID 9805207
  3. Forsyth LM, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999. PMID 10071523
  4. Castro-Marrero J, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal 2015. PMC4346380
  5. Birkmayer GD, Kay GG, Vurre E. Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit. Wien Med Wochenschr 2002. PMID 12385067
  6. Castro-Marrero J, et al. Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Nutrients 2021. PMC8399248
  7. Alegre J, et al. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Rev Clin Esp 2010. PMID 20447621
  8. Castro-Marrero J, et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome. Clin Nutr 2016. PMID 26212172
  9. Birkmayer W, et al. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neural Transm Park Dis Dement Sect 1989. PMID 2597315
  10. Birkmayer JG, et al. Nicotinamide adenine dinucleotide (NADH): a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993. PMID 8101414
  11. ClinicalTrials.gov. NCT03186027. Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. NCT03186027
  12. ClinicalTrials.gov. NCT02063126. Clinical Trial to Measure the Maximun HR After ReConnect Supplementation vs. Placebo in CFS. NCT02063126
  13. Birkmayer JG, Nadlinger K. Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats. Drugs Exp Clin Res 2002. PMID 12635493
  14. Birkmayer JG, Nadlinger KF, Hallstrom S. On the safety of reduced nicotinamide adenine dinucleotide (NADH). J Environ Pathol Toxicol Oncol 2004. PMID 15312041
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list